Stealth Biotherapeutics Announces FDA Acceptance of New Drug Application for Elamipretide for the Treatment of Barth Syndrome Press Release / April 8, 2024June 3, 2024
Stealth BioTherapeutics Presents Data of Novel Compound, SBT-589, in Friedreich’s Ataxia Cardiac Models at the Wellcome Trust Mitochondrial Medicine Conference Press Release / March 19, 2024June 3, 2024
Stealth BioTherapeutics to Present at the Baird 2023 Biotech Discovery Series Press Release / December 4, 2023June 3, 2024
Stealth BioTherapeutics to Present at the 2023 Ophthalmology Innovation Source Summit Press Release / November 28, 2023June 3, 2024
Stealth BioTherapeutics Completes Target Enrollment in Global Phase 3 NuPOWER Trial in Patients with Primary Mitochondrial Myopathy Press Release / September 11, 2023June 3, 2024
Stealth BioTherapeutics Awarded Grant from The Michael J. Fox Foundation to Support Development of SBT-272 in Parkinson’s Disease Press Release / August 9, 2023June 3, 2024
Stealth BioTherapeutics CEO Reenie McCarthy Highlights Opportunities and Challenges in Ultra-Rare Disease Drug Development at World Orphan Drug Congress USA Event / June 14, 2023June 3, 2024
Stealth BioTherapeutics Announces Positive End-of-Phase 2 Meeting with FDA on the Development of Elamipretide in Patients with Dry Age-related Macular Degeneration Press Release / June 12, 2023June 3, 2024
Stealth BioTherapeutics Enters into Exclusive Licensing Agreement with Pharmanovia to Commercialize Elamipretide for the Treatment of Barth Syndrome in Europe and Key Global Territories Press Release / May 30, 2023June 3, 2024
Stealth BioTherapeutics Presents at the 2023 JMP Securities Life Sciences Conference Event / May 15, 2023May 16, 2023
